Galectin Therapeutics
GALT
GALT
61 hedge funds and large institutions have $8.05M invested in Galectin Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
8% less call options, than puts
Call options by funds: $84K | Put options by funds: $91K
29% less capital invested
Capital invested by funds: $11.3M → $8.05M (-$3.26M)
Holders
61
Holding in Top 10
–
Calls
$84K
Puts
$91K
Top Buyers
| 1 | +$74K | |
| 2 | +$71.1K | |
| 3 | +$40K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.5K |
| 5 |
VF
Virtu Financial
New York
|
+$29.6K |
Top Sellers
| 1 | -$45.3K | |
| 2 | -$39K | |
| 3 | -$35.9K | |
| 4 |
WANY
Wealthspire Advisors (New York)
New York
|
-$28K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$22K |